Review





Similar Products

mt-sdna screening test  (Wolters Kluwer Health)
90
Wolters Kluwer Health mt-sdna screening test
Mt Sdna Screening Test, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mt-sdna screening test/product/Wolters Kluwer Health
Average 90 stars, based on 1 article reviews
mt-sdna screening test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multi-target stool dna (mt-sdna) test (marketed as cologuard)  (Exact Sciences Corporation)
90
Exact Sciences Corporation multi-target stool dna (mt-sdna) test (marketed as cologuard)
Multi Target Stool Dna (Mt Sdna) Test (Marketed As Cologuard), supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multi-target stool dna (mt-sdna) test (marketed as cologuard)/product/Exact Sciences Corporation
Average 90 stars, based on 1 article reviews
multi-target stool dna (mt-sdna) test (marketed as cologuard) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
triennial mt-sdna test  (Guardant Health)
90
Guardant Health triennial mt-sdna test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Triennial Mt Sdna Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/triennial mt-sdna test/product/Guardant Health
Average 90 stars, based on 1 article reviews
triennial mt-sdna test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mt-sdna test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals mt-sdna test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mt-sdna test/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
mt-sdna test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
stool dna (mt-sdna) test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals stool dna (mt-sdna) test
Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
Stool Dna (Mt Sdna) Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stool dna (mt-sdna) test/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
stool dna (mt-sdna) test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
next-generation mt-sdna test  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals next-generation mt-sdna test
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Next Generation Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/next-generation mt-sdna test/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
next-generation mt-sdna test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mt-sdna tests  (Exact Sciences Corporation)
90
Exact Sciences Corporation mt-sdna tests
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Mt Sdna Tests, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mt-sdna tests/product/Exact Sciences Corporation
Average 90 stars, based on 1 article reviews
mt-sdna tests - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multi-target stool dna (mt-sdna) screening test  (Exact Sciences Corporation)
90
Exact Sciences Corporation multi-target stool dna (mt-sdna) screening test
<t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
Multi Target Stool Dna (Mt Sdna) Screening Test, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multi-target stool dna (mt-sdna) screening test/product/Exact Sciences Corporation
Average 90 stars, based on 1 article reviews
multi-target stool dna (mt-sdna) screening test - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test <xref ref-type= a " width="100%" height="100%">

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test a

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

Projected Cost-Effectiveness Outcomes <xref ref-type= a " width="100%" height="100%">

Journal: JAMA Network Open

Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

doi: 10.1001/jamanetworkopen.2024.54938

Figure Lengend Snippet: Projected Cost-Effectiveness Outcomes a

Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

Techniques:

ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques:

Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

Journal: Gastro Hep Advances

Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

doi: 10.1016/j.gastha.2024.05.002

Figure Lengend Snippet: Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

Techniques: